AAPL   277.99 (+1.63%)
FB   189.64 (-0.06%)
MSFT   162.23 (+2.55%)
GOOGL   1,306.75 (-0.62%)
AMZN   1,872.12 (-0.65%)
NVDA   271.85 (+7.62%)
MU   52.82 (+4.43%)
AMD   45.36 (+3.07%)
T   35.12 (-1.71%)
ACB   1.38 (-4.84%)
NFLX   370.83 (-0.24%)
BAC   28.49 (-2.20%)
GILD   69.27 (-4.67%)
DIS   116.36 (-1.42%)
AAPL   277.99 (+1.63%)
FB   189.64 (-0.06%)
MSFT   162.23 (+2.55%)
GOOGL   1,306.75 (-0.62%)
AMZN   1,872.12 (-0.65%)
NVDA   271.85 (+7.62%)
MU   52.82 (+4.43%)
AMD   45.36 (+3.07%)
T   35.12 (-1.71%)
ACB   1.38 (-4.84%)
NFLX   370.83 (-0.24%)
BAC   28.49 (-2.20%)
GILD   69.27 (-4.67%)
DIS   116.36 (-1.42%)
AAPL   277.99 (+1.63%)
FB   189.64 (-0.06%)
MSFT   162.23 (+2.55%)
GOOGL   1,306.75 (-0.62%)
AMZN   1,872.12 (-0.65%)
NVDA   271.85 (+7.62%)
MU   52.82 (+4.43%)
AMD   45.36 (+3.07%)
T   35.12 (-1.71%)
ACB   1.38 (-4.84%)
NFLX   370.83 (-0.24%)
BAC   28.49 (-2.20%)
GILD   69.27 (-4.67%)
DIS   116.36 (-1.42%)
AAPL   277.99 (+1.63%)
FB   189.64 (-0.06%)
MSFT   162.23 (+2.55%)
GOOGL   1,306.75 (-0.62%)
AMZN   1,872.12 (-0.65%)
NVDA   271.85 (+7.62%)
MU   52.82 (+4.43%)
AMD   45.36 (+3.07%)
T   35.12 (-1.71%)
ACB   1.38 (-4.84%)
NFLX   370.83 (-0.24%)
BAC   28.49 (-2.20%)
GILD   69.27 (-4.67%)
DIS   116.36 (-1.42%)
Log in

NASDAQ:EXEL - Exelixis Stock Price, Forecast & News

$18.54
+0.11 (+0.60 %)
(As of 02/28/2020 11:43 AM ET)
Today's Range
$17.70
Now: $18.54
$18.65
50-Day Range
$17.20
MA: $19.25
$21.80
52-Week Range
$15.02
Now: $18.54
$25.31
Volume1.45 million shs
Average Volume3.39 million shs
Market Capitalization$5.66 billion
P/E Ratio18.17
Dividend YieldN/A
Beta1.93
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.78 million
Cash Flow$1.50 per share
Book Value$4.31 per share

Profitability

Net Income$690.07 million

Miscellaneous

Employees484
Market Cap$5.66 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.


Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings data on Tuesday, February, 25th. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.07. The biotechnology company had revenue of $240.31 million for the quarter, compared to analyst estimates of $240.49 million. Exelixis had a return on equity of 21.51% and a net margin of 33.17%. Exelixis's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.37 EPS. View Exelixis' Earnings History.

When is Exelixis' next earnings date?

Exelixis is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Exelixis.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $850-900 million, compared to the consensus revenue estimate of $944.08 million.

What price target have analysts set for EXEL?

12 equities research analysts have issued 1 year price objectives for Exelixis' stock. Their forecasts range from $20.00 to $35.00. On average, they expect Exelixis' stock price to reach $25.60 in the next twelve months. This suggests a possible upside of 38.1% from the stock's current price. View Analyst Price Targets for Exelixis.

What is the consensus analysts' recommendation for Exelixis?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Has Exelixis been receiving favorable news coverage?

News coverage about EXEL stock has been trending extremely negative this week, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Exelixis earned a news sentiment score of -4.4 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Exelixis.

Are investors shorting Exelixis?

Exelixis saw a decline in short interest in February. As of February 14th, there was short interest totalling 16,120,000 shares, a decline of 12.4% from the January 30th total of 18,410,000 shares. Based on an average daily volume of 3,100,000 shares, the days-to-cover ratio is currently 5.2 days. Approximately 5.5% of the company's stock are short sold. View Exelixis' Current Options Chain.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), BioMarin Pharmaceutical (BMRN), Corbus Pharmaceuticals (CRBP) and Cisco Systems (CSCO).

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:
  • Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.91%), State Street Corp (3.64%), FMR LLC (3.21%), AJO LP (2.51%), AQR Capital Management LLC (2.50%) and Farallon Capital Management LLC (2.47%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, FMR LLC, Goldman Sachs Group Inc., Pictet Asset Management Ltd., Great West Life Assurance Co. Can, Fiera Capital Corp, UBS Group AG and Prudential Financial Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Which institutional investors are buying Exelixis stock?

EXEL stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, AJO LP, Bank of Montreal Can, Renaissance Technologies LLC, State Street Corp, First Trust Advisors LP, Acadian Asset Management LLC and Man Group plc. View Insider Buying and Selling for Exelixis.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $18.54.

How big of a company is Exelixis?

Exelixis has a market capitalization of $5.66 billion and generates $967.78 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.02 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

What is Exelixis' official website?

The official website for Exelixis is http://www.exelixis.com/.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (NASDAQ EXEL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  470 (Thanks for Voting!)
Underperform Votes:  430 (Thanks for Voting!)
Total Votes:  900
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Most Volatile Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel